An Open-Label Phase 2 Proof or Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471

Site Image

Study Overview

This is an open-label study of 12 months of dosing with ACH-0144471. The study will enroll patients with biopsy-confirmed C3G or IC-MPGN who meet eligibility criteria for this study. There will be a multi-step screening process. At the initial screening visit, all screening eligibility assessments, except the renal biopsy, will be performed. If the subject remains eligible based on the results from the initial screening visit, then arrangements can be made for renal biopsy and vaccinations. The initial screening visit must occur no more than 75 days before the first dose date. The renal biopsy must occur no more than 30 days before the first dose, but will be targeted to occur approximately two weeks prior to the first dose of ACH-0144471.

Additional Information:

For any questions related to the study, please contact the study coordinators below:
Stacey Lau -; (215)220-9544
Krishna Kallem -; (484)358-0315

  • Study Identifier: 830210

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email